Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.
2018 ◽
Vol 36
(15_suppl)
◽
pp. 1049-1049
◽